PCAS

Earnings Release • Nov 21, 2018

DECREASE ON 2018 RESULTS

Longjumeau, November 21st , 2018

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, communicates today on its activity and results expected for 2018.

On 7th November 2018, we announced that:

• The Group's net sales for 2018 were expected to be close to 2017 level;
• Operational difficulties had been faced over the last 2 months, reducing some plants' production capacities; and that, as a consequence, the Group's results could be significantly affected should these issues continue during the last months of 2018, given the high level of activity towards the end of the year or if the American currency were to weaken against the euro.

Operational difficulties are still on going, in particular at one production plant of the Group. The Group's net sales and results 2018 will be below 2017 levels.

All of the Group's teams are heavily involved to ensure that the financial impacts will be as limited as possible.

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for marketleading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €218.3 million in 2017 and employs close to 1 100 people in six countries.

To find out more about PCAS, visit: www.pcas.com

PCAS	Newcap
Vincent Touraille / Eric Moissenot PCAS	Emmanuel Huynh / Louis-Victor Delouvrier NewCap Communication financière et Relations Investisseurs
Tél. : +33 1 69 79 61 32 www.pcas.com	Tél. : +33 1 44 71 98 53 pcas@newcap.eu